Develops masked biologic cancer drug candidates for patients with colorectal cancer, melanoma and other solid tumors.
10-K for FY2025, filed Mar 16, 2026We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet…View ↗
Our most advanced clinical-stage program is Varseta-M, an investigational, conditionally activated antibody-drug conjugate (“ADC”)…View ↗
In addition to Varseta-M, our pipeline includes CX-801, an investigational, masked version of interferon alpha-2b (“IFNα2b”), currently in…View ↗
For CX-801, we have also employed a focused initial development strategy in Phase 1, centered on the treatment of late-line melanoma where…View ↗
$76.2M
10-K for FY2025, filed Mar 16, 2026
$76.2M ↗Works with biopharmaceutical companies through strategic research alliances; revenue is reported from Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna.
No. It lost $17.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$20MView ↗
8-K, filed Jun 3, 2026
Additionally, in connection with Amendment No. 4, Regeneron nominated the first two additional collaboration programs under the Agreement…View ↗
Growing. Revenue grew 2.0x in 4 years, from $37.3M in FY2021 to $76.2M in FY2025, about 20% a year.
Candidates advance to clinical testing
The older report placed an EpCAM-targeting antibody-drug conjugate and a masked interferon candidate in preclinical development; the latest report describes those programs as clinical-stage.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 16, 2026We also have a broad pre-clinical pipeline across our collaborations and internally, including two wholly-owned next-generation molecules…View ↗
CytomX’s two current clinical programs, varsetatug masetecan (“Varseta-M”) and CX-801 are in Phase 1 clinical development and are examples…View ↗
Our most advanced clinical-stage program is Varseta-M, an investigational, conditionally activated antibody-drug conjugate (“ADC”)…View ↗
In addition to Varseta-M, our pipeline includes CX-801, an investigational, masked version of interferon alpha-2b (“IFNα2b”), currently in…View ↗
Competes with AbbVie, Adagene, Amgen, BioAtla, Halozyme Therapeutics, Merck, Roche, Sanofi, Takeda Pharmaceutical, Werewolf Therapeutics, Janux Therapeutics, Xilio Therapeutics, Vir Biotechnology, Daiichi Sankyo, Gilead Sciences, Pfizer, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, and Novartis
10-K for FY2025, filed Mar 16, 2026Masking and conditional activation: Several companies, including AbbVie, Adagene, Amgen, BioAtla, Halozyme Therapeutics, Merck, Roche…View ↗
Loading...